Cantor Fitzgerald Reiterates Overweight Rating on SI-BONE Inc. (SIBN)

Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $25.00 price target on SI-BONE Inc. (NASDAQ: SIBN).

The analyst commented, “On 8/4, SI-BONE (SIBN, OW) reported comprehensive 2Q25 operating results and increased FY25 revenue guidance. Specifically, SIBN reported 2Q25 revenue of $48.6 million (Cantor $48.1 million / FactSet consensus $48.1 million), representing YoY growth of ~22% driven by U.S. revenue, which grew ~23% YoY to $46.4 million. The company had over 1,440 active U.S. surgeons (+~25% YoY) in the quarter, as the company's sales representatives generated production of ~$2.1 million, up ~23% YoY. Looking ahead, we believe guidance remains conservative given early success with iFuse TORQ TNT, which is ramping ahead of expectations and now supported by finalized NTAP reimbursement (~$4,100 per case) starting in 4Q25. Additionally, adoption within the interventionalist community continues to build, and we see a pathway for increased utilization as the company plans to roll out a new SI Joint product in 1H26 that will further expand engagement with interventionalists.”

For an analyst ratings summary and ratings history on SI-BONE Inc. click here. For more ratings news on SI-BONE Inc. click here.

Shares of SI-BONE Inc. closed at $15.68 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)